Sam Chawla Net Worth

The estimated Net Worth of Sam Chawla is at least $654 Tausend dollars as of 30 October 2017. Sam Chawla owns over 3,100,000 units of VBI Vaccines stock worth over $654,201 and over the last 8 years Sam sold VBIV stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Sam Chawla VBIV stock SEC Form 4 insiders trading

Sam has made over 1 trades of the VBI Vaccines stock since 2017, according to the Form 4 filled with the SEC. Most recently Sam bought 3,100,000 units of VBIV stock worth $9,455,000 on 30 October 2017.

The largest trade Sam's ever made was buying 3,100,000 units of VBI Vaccines stock on 30 October 2017 worth over $9,455,000. On average, Sam trades about 1,033,333 units every 0 days since 2017. As of 30 October 2017 Sam still owns at least 9,345,725 units of VBI Vaccines stock.

You can see the complete history of Sam Chawla stock trades at the bottom of the page.

What's Sam Chawla's mailing address?

Sam's mailing address filed with the SEC is C/O VBI VACCINES INC., 222 THIRD STREET, STE 2241, CAMBRIDGE, MA, 02142.

Insiders trading at VBI Vaccines

Over the last 8 years, insiders at VBI Vaccines have traded over $18,633,012 worth of VBI Vaccines stock and bought 55,142,222 units worth $66,770,591 . The most active insiders traders include Advisors Llcperceptive Life..., Tomer Kariv und Steven D Rubin. On average, VBI Vaccines executives and independent directors trade stock every 62 days with the average trade being worth of $130,457. The most recent stock trade was executed by Steven Gillis on 10 July 2023, trading 609,090 units of VBIV stock currently worth $1,004,999.

What does VBI Vaccines do?

vbi vaccines inc. (nasdaq: vbiv) is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. vbi’s evlp vaccine platform allows for the design of enveloped (“e”) virus-like particle (“vlp”) vaccines that closely mimic the target virus. the company’s lead evlp asset is a prophylactic cytomegalovirus (cmv) vaccine; vbi has initiated work for gmp manufacturing of its cmv candidate for use in formal preclinical and phase i trials. the company’s second platform is a thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. vbi has completed proof of concept thermostability studies on a number of vaccine and biologic targets. vbi is headquartered in cambridge, ma with research facilities in ottawa, canada.

Complete history of Sam Chawla stock trades at VBI Vaccines

VBI Vaccines executives and stock owners

VBI Vaccines executives and other stock owners filed with the SEC include:

• Jeffrey Baxter,
  President, Chief Executive Officer, Director
• Jeffery R. Baxter F.C.M.A., FCMA,
  Pres, CEO & Director
• Francisco Diaz-Mitoma,
  Chief Medical Officer
• David Anderson,
  Chief Scientific Officer
• Jeffrey R. Baxter F.C.M.A., FCMA,
  Pres, CEO & Director
• Steven Gillis,
  Independent Chairman of the Board
• Dr. Francisco Diaz-Mitoma FRCPC, M.D., Ph.D.,
  Chief Medical Officer
• Blaine Mckee,
  Independent Director
• Dr. David Evander Anderson,
  Chief Scientific Officer
• Joanne Cordeiro,
  Independent Director
• Michel Wilde,
  Independent Director
• Christopher McNulty,
  CFO & Head of Bus. Devel.
• Nicole Anderson,
  Investor Relations
• Damian Braga,
  Independent Director
• Avi Mazaltov,
  Global Head of Manufacturing and SciVac General Manager
• Nell Beattie,
  Chief Business Officer
• Christopher McNulty,
  Chief Financial Officer and Head of Business Development, Director
• Avi Mazaltov,
  Global Head of Manufacturing & GM of SciVac
• Nell Beattie,
  Chief Bus. Officer
• T. Adam Buckley,
  Sr. VP of Bus. Devel.
• Misha Nossov,
  Sr. VP of Market Access & Commercial
• Athena Kartsaklis,
  Sr. VP of Fin., Chief Compliance Officer & Principal Financial Officer
• Scott Requadt,
  Director
• Catherine Eckenswiller,
  Contracts and IP Counsel
• Sam Chawla,
  Director
• Egidio Nascimento,
  Chief Financial Officer
• Adam Logal,
  Director
• Jeff Baxter,
  CEO, President
• T. Adam Buckley,
  VP, Business Development
• Steven D Rubin,
  Director
• Advisors Llcperceptive Life...,
  
• Health, Inc. Opko,
  10% owner
• Tomer Kariv,
  Director
• Athena Kartsaklis,
  SVP Finance, CCO
• Vaughn B Himes,
  Director
• Linda Bain,
  Director
• John Robert Dillman,
  Chief Commercial Officer